Why You Don't Need to Cycle CJC-1295 or Tesamorelin

The standard advice is to cycle CJC-1295 and Ipamorelin on a three months on, one month off schedule. And that advice is not wrong, but it is incomplete in a way that changes everything about how you should think about these compounds.

The reason it is incomplete is that CJC and Ipamorelin almost always come packaged together in the same vial, so the cycling advice gets applied to the combination as though both compounds have the same problem. They do not. To understand why, you need to know how each one actually works inside your pituitary gland.

Your pituitary releases growth hormone in response to two separate receptor systems. The first is something called the GHRH receptor, which responds to a signal called growth hormone releasing hormone and essentially tells the pituitary to produce and release growth hormone. The second is something called the ghrelin receptor, which responds to a different class of signals and acts more like an amplifier, boosting the size of the growth hormone pulse that the GHRH signal already started. CJC-1295 and tesamorelin work on the first system. Ipamorelin works on the second.

That distinction matters because those two receptor systems do not behave the same way when you stimulate them repeatedly over time.

When you stimulate ghrelin receptors continuously, your body begins a process called beta arrestin mediated internalization, which is when the receptor itself gets pulled off the surface of the cell and stored inside it so it can no longer respond to the signal coming in. This is not a drug side effect. It is a normal biological safeguard against any receptor getting overstimulated, and it happens throughout the body in dozens of receptor systems. The more you stimulate the receptor without giving it recovery time, the fewer of those receptors remain available on the cell surface, and the weaker your growth hormone response becomes.

A 16-week human trial tracked exactly this. Subjects given continuous ghrelin receptor stimulation saw their growth hormone response fall by about 45 percent from baseline by week 16. Then they stopped for four weeks and response came all the way back to where it started. That recovery pattern is the whole reason the three on, one off cycle exists. The break is not arbitrary. It is the time your body needs to recycle those receptors back to the surface.

So now the question is whether the same thing happens to GHRH receptors when you stimulate them with tesamorelin or CJC.

The short answer from the clinical data is no, and there are two reasons for that.

The first reason is receptor biology. A study using perifused rat pituitary cells showed that the GHRH receptor system and the ghrelin receptor system are genuinely independent, meaning that stimulating one does not deplete the other, and that each system desensitizes through its own separate mechanism. This matters because it rules out the idea that CJC could be silently burning out your ghrelin receptors or vice versa.

The second reason is pharmacokinetics, which is just a word for how long a compound stays active in your body. Tesamorelin has a half life of roughly 30 minutes. You inject it, it signals your GHRH receptors for a short window, and then it clears. Your receptors then have more than 23 hours of quiet time before the next dose arrives. That recovery window is the difference. The receptor gets a signal, responds, and then resets before it is asked to respond again.

The clinical data reflects this. In the Phase 3 trials that led to FDA approval, tesamorelin was given by daily injection for 52 weeks straight and IGF-1 levels held steady across that entire period with no decline. The 26-week data from the NEJM trial showed the same thing. If GHRH receptor desensitization were happening the way ghrelin receptor desensitization happens, you would expect to see IGF-1 start dropping somewhere in that window. It does not.

Ipamorelin, by contrast, has a shorter half life than tesamorelin but it is being dosed more frequently and in a pattern that does not give ghrelin receptors the same extended recovery window. That is why the receptor internalization problem shows up with ghrelin-based peptides and not with GHRH-based ones.

There is also longer-term data on a ghrelin receptor agonist called MK-677, which works through the same ghrelin receptor system as Ipamorelin. In a two-year study in older adults, continuous daily MK-677 maintained IGF-1 elevation across the full period, which seems to contradict the desensitization story until you look at the mechanism. MK-677 has a much longer half life than Ipamorelin, which changes the receptor binding dynamics in ways that may reduce internalization. The point is that receptor behavior depends heavily on how long a compound is present and at what concentration, not just which receptor it targets.

For practical purposes, this means that if you are running CJC and Ipamorelin together, you cycle because of the Ipamorelin. The CJC does not need the break. If you are running tesamorelin by itself, there is no published evidence that a cycling protocol is required, and the 52-week data actively argues against the assumption that one is.

The deeper point is that the biology of peptide cycling is not really about the compound itself. It is about which receptor the compound uses and whether that receptor has a meaningful internalization response to the way you are dosing it. Two peptides can sit in the same vial, work toward the same outcome, and still have completely different requirements. Treating them as one thing because they come packaged together means cycling something that does not need to be cycled and potentially missing the reason you were cycling in the first place.

---

References

1. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143 — 16-week human trial showing 45% GH response decline with continuous ghrelin receptor stimulation, full recovery after 4 weeks off. Source
2. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin daily dosing for 26 weeks with sustained IGF-1 elevation. Source
3. FDA Prescribing Information. EGRIFTA (tesamorelin). 2010/2025 — 52-week pooled Phase 3 data showing sustained IGF-1 and VAT reduction through week 52
4. Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells. J Endocrinol. 1991;1291:11-19 — Proved GHRH and ghrelin receptor systems are independent with no cross-desensitization. Source
5. Nass R et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;1499:601-611 — MK-677 ghrelin mimetic maintained GH/IGF-1 elevation for 2 years of continuous use. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness